Financials data is unavailable for this security.
View more
Year on year Beijing Wantai Biological Pharmacy Enterprise Co Ltd 's revenues fell -50.73% from 11.19bn to 5.51bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 4.74bn to 1.25bn, a -73.65% decrease.
| Gross margin | 69.01% |
|---|---|
| Net profit margin | -11.84% |
| Operating margin | -13.61% |
| Return on assets | -1.89% |
|---|---|
| Return on equity | -2.29% |
| Return on investment | -2.26% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Beijing Wantai Biological Pharmacy Enterprise Co Ltd fell by 1.40bn. However, the company earned 1.54bn from its operations for a Cash Flow Margin of 27.91%. In addition the company used 2.05bn on investing activities and also paid 893.26m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 9.82 |
|---|---|
| Tangible book value per share | 9.28 |
More ▼
Balance sheet in CNYView more
| Current ratio | 4.61 |
|---|---|
| Quick ratio | 4.18 |
| Total debt/total equity | 0.0248 |
|---|---|
| Total debt/total capital | 0.0238 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -55.20% and -73.90%, respectively. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
| EPS growth(5 years) | 29.25 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -111.65 |
